Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004352 (
autism
)
32,579
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Abnormal synaptic formation and signaling is one of the key molecular features of
autism
spectrum disorders (ASD).
Cortactin binding protein 2
(
CTTNBP2
), an ASD-linked gene, is known to regulate the subcellular distribution of synaptic proteins, such as cortactin, thereby controlling dendritic spine formation and maintenance. However, it remains unclear how ASD-linked mutations of
CTTNBP2
influence its function. Here, using cultured hippocampal neurons and knockin mouse models, we screen seven ASD-linked mutations in the short form of the Cttnbp2 gene and identify that M120I, R533* and D570Y mutations impair
CTTNBP2
protein-protein interactions via divergent mechanisms to reduce dendritic spine density in neurons. R533* mutation impairs
CTTNBP2
interaction with cortactin due to lack of the C-terminal proline-rich domain. Through an N-C terminal interaction, M120I mutation at the N-terminal region of
CTTNBP2
also negatively influences cortactin interaction. D570Y mutation increases the association of
CTTNBP2
with microtubule, resulting in a dendritic localization of
CTTNBP2
, consequently reducing the distribution of
CTTNBP2
in dendritic spines and impairing the synaptic function of
CTTNBP2
. Finally, we generated heterozygous M120I knockin mice to mimic the genetic variation of patients and found they exhibit reduced social interaction. Our study elucidates that different ASD-linked mutations of
CTTNBP2
result in diverse molecular deficits, but all have the similar consequence of synaptic impairment.
...
PMID:Autism-linked mutations of CTTNBP2 reduce social interaction and impair dendritic spine formation via diverse mechanisms. 3316 5